The stock of Creative Medical Technology Holdings Inc (CELZ) closed the recent trading session at $1.57, gaining 5.37% from the previous trading session. During the last check, the stock of CELZ soared in the after-market, gaining 19.75%.
CELZ News
CELZ filed form 8-K with the SEC earlier this month to report the employment agreements. CEO and CFO entered into an agreement regarding the base salary, with the company. According to the agreement, the base salary of Mr. Timothy Warbington, CEO, remains $0.33 million per year. While the base salary of Mr. Donald Dickerson, CFO, remains $0.30 million annually. Further terms of the agreement are
- The employment agreement is for three years.
- Each executive can get a 30% cash bonus of their base salary, per year.
- Every Executive is qualified for a yearly grant of a choice to buy various shares of normal stock of the Company with a worth of 30% of the Executive’s base compensation.
- In case of termination, the executive will be qualified for the payment of base compensation and yearly rewards for two years.
On December 3, 2021, CELZ also announced the public offering of its 3.8 million shares at the total cost of $16 million, at a price of $4.13 per share. Moreover, the company said that it has now exhibited early achievement in animal models and at present has a forthcoming Investigational New Drug Application recorded with the FDA.
About CELZ
Creative Medical Technology Holdings, Inc (CELZ) is a biotech organization that is occupied with the advancement of urology, orthopedics, and nervous system science utilizing adult stem cell therapies. CELZ stock has a market cap of $21.38 million. CELZ is propelling the way that organizations address different immunity issues. Its ImmCelz stage is intended to “reinvent” immune cells in stroke patients. The company was founded in 1998 and has its base in Phoenix, Arizona, United States of America (USA).
Conclusion
The COVID-19 pandemic has prodded widespread development across the sub-sectors of the medical care industry for a while now, making this an appealing industry for investors. Things are working out positively for CELZ stock regardless of the shortfall of any stock news. It would be intriguing to perceive how lengthy this pattern will stay as the stock market is exceptionally eccentric.
